



## Review

Cytogenetic biomarkers in detection of genotoxic effects of gestagens in peripheral blood lymphocytes *in vitro* and *in vivo*

Darko Grujić <sup>a, \*</sup>, Marina Radović <sup>a</sup>, Slobodan Arsenijević <sup>b, c</sup>,  
Olivera Milošević-Djordjević <sup>a, b</sup>

<sup>a</sup> Faculty of Science, University of Kragujevac, 34 000, Kragujevac, Serbia

<sup>b</sup> Faculty of Medical Sciences, University of Kragujevac, 34 000, Kragujevac, Serbia

<sup>c</sup> Gynaecology Clinic, Clinical Centre Kragujevac, 34 000, Kragujevac, Serbia

## ARTICLE INFO

## Article history:

Received 5 July 2016

Received in revised form

28 September 2016

Accepted 24 October 2016

Available online 26 October 2016

## Keywords:

Genotoxicity

Gestagens

Micronuclei

Peripheral blood lymphocytes

Pregnancy

## ABSTRACT

Gestagens are the most frequently used steroid hormones in hormone-replacement therapy in the treatment of threatened miscarriage during the first trimester of pregnancy. This therapy has been applied in a large number of women with threatened abortion, despite various degrees of success of its efficacy. Genetic factors play a key role in miscarriages, especially in the initial stages. Cytogenetic biomarkers such as micronucleus (MN) test, chromosomal aberrations (CAs), and sister chromatid exchanges (SCEs) provide information on DNA damage. Cytogenetic markers detecting DNA damage have become very popular and useful in analysing genetic risk associated with hormone-replacement therapy. Cytogenetic studies presented heterogeneous information. In many *in vitro* studies synthetic gestagens have been shown to induce genotoxic effects, and it was evaluated using three cytogenetic biomarkers. Genotoxic effects of gestagens have also been confirmed in *in vivo* studies that were conducted involving patients who received gestagen therapy during pregnancy and their newborns. However, some studies have shown that hormone-replacement therapy does not have genotoxic effects. In this paper, we summarize the results from previous studies. We also describe the usefulness of these biomarkers in the detection of genotoxic effects of hormone-replacement therapy.

© 2016 Elsevier Masson SAS. All rights reserved.

## Contents

1. Introduction .....	624
2. Micronucleus (MN) test .....	625
3. Test for chromosomal aberrations (CAs) .....	627
4. Sister chromatid exchanges (SCEs) .....	627
5. Genotoxic effect of hormone replacement .....	627
5.1. In vitro genotoxicity of gestagens .....	627
5.2. In vivo genotoxicity of gestagens .....	627
5.2.1. The effects of gestagens on MN frequency in pregnant women .....	627
5.2.2. The effects of gestagens on MN frequency in newborns .....	629
6. Conclusion .....	631
Conflict of interest .....	631
Acknowledgements .....	631
References .....	631

## 1. Introduction

Miscarriage is an embryonic or fetal loss occurring before 20 weeks' gestation (Porter and Scott, 2005). Many factors, such as

\* Corresponding author. Faculty of Science, University of Kragujevac, Radoja Domanovića 12, 34 000, Kragujevac, Serbia, Tel.: +381 34 335 039, fax: +381 34 335 040.

E-mail address: [darko@kg.ac.rs](mailto:darko@kg.ac.rs) (D. Grujić).

















